Technologies Energizing Oncolytic Adenoviruses

Technologies Energizing Oncolytic Adenoviruses

RELEASE DATE
28-Sep-2018
REGION
Global
Research Code: D758-00-8D-00-00
SKU: HC03091-GL-TA_22392

$250.00

Special Price $187.50 save 25 %

In stock
SKU
HC03091-GL-TA_22392

$250.00

$187.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This Genetic Technology TOE encompasses recent advances in oncolytic viral platforms, while outlining the overall impact of gene therapy. Furthermore, this TOE covers the overview, technological capabilities, IP trends, clinical trial snapshot, and strategic insights for Sagetis Biotech.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Gene therapy, oncolytic virus, adenovirus, Sagetis, Biotech, Viroshield, AdNuPARmE1A, Duchenne’s muscular dystrophy (DMD), pancreatic cancer, rare diseases, SAG-101, pancreatic ductal adenocarcinoma (PDAC)

Table of Contents

Recent Advances in Oncolytic Viruses

  • Gene Therapy – Overall Impact and Opportunity Leverage
  • VIROSHIELD™ Platform Technology
  • Oncolytic Virus Innovation Scouting
  • VIROSHIELD™ Platform: Approaches and Features

Clinical Trial Analysis and Key Contacts

  • Sagetis Biotech’s VIROSHIELD™ Platform
  • Key Contacts
Related Research
This Genetic Technology TOE encompasses recent advances in oncolytic viral platforms, while outlining the overall impact of gene therapy. Furthermore, this TOE covers the overview, technological capabilities, IP trends, clinical trial snapshot, and strategic insights for Sagetis Biotech. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Gene therapy, oncolytic virus, adenovirus, Sagetis, Biotech, Viroshield, AdNuPARmE1A, Duchenne’s muscular dystrophy (DMD), pancreatic cancer, rare diseases, SAG-101, pancreatic ductal adenocarcinoma (PDAC)
More Information
No Index No
Podcast No
Industries Healthcare
WIP Number D758-00-8D-00-00
Is Prebook No
Ti Codes D753,D904,D913,D91A,D91B,D932,D933,D935